Related references
Note: Only part of the references are listed.Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan
Koji Izutsu et al.
CANCER SCIENCE (2021)
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response
Wendy Beguelin et al.
CANCER CELL (2020)
EZH2-activating mutation: no reliable indicator for efficacy of methyltransferase inhibitors
Hilmar Quentmeier et al.
LEUKEMIA & LYMPHOMA (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features
Yang Liu et al.
HUMAN PATHOLOGY (2017)
Molecular basis of USP7 inhibition by selective small-molecule inhibitors
Andrew P. Turnbull et al.
NATURE (2017)
Genome Regulation by Polycomb and Trithorax: 70 Years and Counting
Bernd Schuettengruber et al.
CELL (2017)
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
V. Gibaja et al.
ONCOGENE (2016)
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
Wendy Beguelin et al.
CANCER CELL (2016)
Distinct features of H3K4me3 and H3K27me3 chromatin domains in pre-implantation embryos
Xiaoyu Liu et al.
NATURE (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation
Zheng Zhou et al.
LEUKEMIA & LYMPHOMA (2015)
Inhibitors of protein methyltransferases as chemical tools
Minkui Luo
EPIGENOMICS (2015)
Germinal centres and B cell lymphomagenesis
Katia Basso et al.
NATURE REVIEWS IMMUNOLOGY (2015)
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation
William D. Bradley et al.
CHEMISTRY & BIOLOGY (2014)
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Hua Yu et al.
NATURE REVIEWS CANCER (2014)
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Junli Yan et al.
BLOOD (2013)
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Csaba Boedoer et al.
BLOOD (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Transcriptional regulation by Polycomb group proteins
Luciano Di Croce et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis
Y-H Fan et al.
CELL DEATH & DISEASE (2013)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson et al.
NATURE CHEMICAL BIOLOGY (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Damian B. Yap et al.
BLOOD (2011)
STAT3 SIGNALING: Anticancer Strategies and Challenges
Paul A. Johnston et al.
MOLECULAR INTERVENTIONS (2011)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Regulation of Stem Cell Pluripotency and Differentiation Involves a Mutual Regulatory Circuit of the Nanog, OCT4, and SOX2 Pluripotency Transcription Factors With Polycomb Repressive Complexes and Stem Cell microRNAs
Vasundhra Kashyap et al.
STEM CELLS AND DEVELOPMENT (2009)
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: Implications for the regulation of the p53-MDM2 pathway
M Hu et al.
PLOS BIOLOGY (2006)
Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells
T Gritsko et al.
CLINICAL CANCER RESEARCH (2006)
STAT3-mediated transcription of Bcl-2, Mcl-1 and c-lAP2 prevents apoptosis in polyamine-depleted cells
S Bhattacharya et al.
BIOCHEMICAL JOURNAL (2005)
Primary cervical lymphoma: Report of two cases and review of the literature
P Dursun et al.
GYNECOLOGIC ONCOLOGY (2005)
The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma
HPJ Visser et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
PK Epling-Burnette et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
